Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations

Mehrnoosh Tashakori, Joseph D. Khoury, Mark J. Routbort, Keyur P. Patel, Sa A. Wang, Chi Young Ok, Siba El-Hussein, Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, Shimin Hu, Pei Lin, Naveen Pemmaraju, Prithviraj Bose, Srdan Verstovsek, Carlos E. Bueso-Ramos, L. Jeffrey Medeiros, Sanam Loghavi

Research output: Contribution to journalArticlepeer-review


Myeloproliferative neoplasms (MPNs) are frequently associated with classic driver mutations involving JAK2, MPL or CALR. SRSF2 is among the most frequently mutated splicing genes in myeloid neoplasms and SRSF2 mutations are known to confer a poor prognosis in patients with MPNs. In this study, we sought to evaluate the clinicopathologic spectrum of myeloid neoplasms harboring concurrent MPN-driver mutations and SRSF2 mutations. The study cohort included 27 patients, 22 (82%) men and five (19%) women, with a median age of 71 years (range, 51–84). These patients presented commonly with organomegaly (n = 15; 56%), monocytosis (n = 13; 48%), morphologic dysplasia (n = 11; 41%), megakaryocytic hyperplasia and/or clustering (n = 10; 37%) and bone marrow fibrosis >MF-1 (17/22; 77%). About one third of patients either initially presented with acute myeloid leukemia (AML) or eventually progressed to AML. Eighteen (68%) patients had a dominant clone with SRSF2 mutation and nine (33%) patients had a dominant clone with a classic MPN-associated driver mutation. Our data suggest that the presence of an SRSF2 mutation preceding the acquisition of a MPN driver mutations is not a disease-defining alteration nor is it restricted to any specific disease entity within the spectrum of myeloid neoplasms. In summary, patients with myeloid neoplasms associated with concurrent SRSF2 and classic MPN driver mutations have clinical and morphologic features close to that of classic MPNs often with frequent dysplasia and monocytosis.

Original languageEnglish (US)
Pages (from-to)1677-1683
Number of pages7
JournalModern Pathology
Issue number11
StatePublished - Nov 2022

Bibliographical note

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations'. Together they form a unique fingerprint.

Cite this